2Dooley M, Balfour JA. Ibandronate [J]. Drugs, 2001;59(1):101-110.
3Berenson JR. New advances in the biology and treatment of myeloma bone disease [J]. Semin Hematol, 2001 ;38(2 Suppl 3):15-20.
4Terpos E, Viniou N, de la Fuente J, et al. Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma [J] . Eur J Haematol, 2003;70(1):34-42.
5Menssen HD, Sakalova A, Fontana A, et al. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival,and bone resorption markers in patients with advanced multiple myeloma[J].J Clin Oncol,2002;20(9):2353-2359.
6Paterson AH. Bisphosphonates: Biological response modifiers in breast cancer [J]. Clin Breast Cancer, 2002;3(3): 206-216.
7Coleman RE, Purohit OP, Black C, et al. Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease [J]. Ann Oncol, 2001;11(3):311-316.
8Puigs,Stauenherz A,Teiner B,et al.Differential,diagnosis of atypically cocated or double hot spots in whole bone scanning [J].Nucl Med,1998,39:1263～1266.
